Skip to main content
. Author manuscript; available in PMC: 2012 May 2.
Published in final edited form as: Neurosci Lett. 2011 Mar 21;494(3):222–226. doi: 10.1016/j.neulet.2011.03.017

Figure 2.

Figure 2

Effects of human NSC transplantation on disease onset (A), life span/survival (B–C) and muscle weakness (D–E) in G93A SOD1 rats.

A. Disease onset was 10 days later in the live-cell group (129.5 ± 3.234 days, n=11) compared to the dead-cell group (119.2 ± 3.709 days, N=11) (P=0.0481).

B. End-point analysis shows that the live-cell group has significantly longer life span compared to dead-cell group (158.9 ± 6.256 days and 141.3 ± 5.494 days, respectively, n=11) (P=0.0469).

C. This Kaplan-Meier plot shows a significant separation between live (L) and dead cell group (D) survival throughout the course of the study (p=0.0402), suggesting animals with live NSCs have better survival.

D–E. BBB (D) and inclined plane (E) scores show a significant separation in these two measures of muscle weakness between live-cell (L) and dead-cell (D) groups (p=0.0183 and 0.045, respectively), suggesting muscle weakness progress is significantly slowed down in animals with live NSCs compared with control animals.

Bar= Mean ±SEM, * P<0.05.